Criticism of tumor response criteria raises trial design questions.
Renee
R
Twombly
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic / Q000592:standards; D018450:Disease Progression; D018572:Disease-Free Survival; D004341:Drug Evaluation / Q000592:standards*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor